Oral News and Research

RSS

New oral blood-thinning drugs may have dangerous interactions when taken with prescription drugs : Study

Three new oral blood-thinning drugs nearing approval by the Food and Drug Administration are more convenient than the standard drug Coumadin® because they do not require monthly visits to adjust doses.

2 Jun 2010

Perrigo acquires rights to Novel Laboratories' pending ANDA for HalfLytely and Bisacodyl Tablets Bowel Prep Kit

Perrigo Company announced on May 26, 2010 that it had acquired rights to Novel Laboratories' pending ANDA for HalfLytely® and Bisacodyl Tablets Bowel Prep Kit (PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution and bisacodyl delayed-release tablets).

2 Jun 2010

Chronix Biomedical to launch new disease detection, monitoring service for cancer researchers at 2010 ASCO

Chronix Biomedical today announced that it will launch a new disease detection and monitoring service for cancer researchers at the upcoming 2010 ASCO Annual Meeting. The "For Investigational Use Only" laboratory-based testing service uses Chronix's breakthrough approach—the Chronix Apoptotic DNA Blood Test—which analyzes apoptotic DNA from dead and dying cells to identify and track ongoing changes associated with specific cancers and other chronic diseases.

2 Jun 2010

Targeted monoclonal antibodies show promise for pancreatic and metastatic breast cancer

Early trials using targeted monoclonal antibodies in combination with existing therapies show promise in treating pancreatic cancer and metastatic breast cancer, according to research that will be presented by investigators from the University of Pennsylvania's Abramson Cancer Center at the 2010 meeting of the American Society of Clinical Oncology June 4 through 8.

2 Jun 2010

Santarus commences enrollment in rifamycin SV MMX Phase III clinical program for travelers' diarrhea

Santarus, Inc., a specialty biopharmaceutical company, today announced that is has begun to enroll patients in the first study in its Phase III clinical program to evaluate the efficacy and safety of rifamycin SV MMX® for the treatment of patients with travelers' diarrhea.

2 Jun 2010

Onyx Pharmaceuticals commences Phase 1 study of ONX 0912 oral proteasome inhibitor for cancer

Onyx Pharmaceuticals, Inc. today announced the initiation of a Phase 1 study of ONX 0912, an oral proteasome inhibitor, in patients with advanced refractory or recurrent solid tumors.

2 Jun 2010

Tetraphase Pharmaceuticals raises $45M in Series C financing

Tetraphase Pharmaceuticals, a clinical stage biopharmaceutical company utilizing breakthrough synthetic chemistry technology to discover and develop next-generation antibiotics, today announced that it has raised $45 million in a Series C financing.

2 Jun 2010

CoaguSense unveils first portable point-of-care PT/INR Monitoring System for patients on oral anticoagulants

CoaguSense™, Inc., a diagnostic device company that has been in stealth mode for the past two years, today unveiled the first portable point-of-care Prothrombin Time/International Normalized Ratio (PT/INR) analyzer to directly detect blood clotting time for patients stabilized on oral anti-coagulation medications such as Coumadin® or warfarin.

2 Jun 2010

Protox announces presentations on PRX302 for BPH at 2010 AUA Annual Meeting

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that two oral podium presentations on the company's lead candidate, PRX302, will be made at the 2010 Annual Meeting of the American Urological Association (AUA). These presentations will include six month data from the Phase 2b clinical study of PRX302 called TRIUMPH, in patients with moderate to severe benign prostatic hyperplasia (BPH).

1 Jun 2010

Centocor Ortho Biotech acquires RespiVert

Centocor Ortho Biotech Inc. today announced that it has acquired RespiVert Ltd., a privately held drug discovery company focused on developing small-molecule, inhaled therapies for the treatment of pulmonary diseases. The company's lead compounds, RV-568 and RV-1088, narrow spectrum kinase inhibitors with a unique profile of anti-inflammatory activities, are progressing into clinical development as potential first-in-class treatments for moderate to severe asthma, Chronic Obstructive Pulmonary Disease (COPD) and Cystic Fibrosis (CF).

1 Jun 2010

OroScience signs agreement with ACE Surgical Supply to market Periogenix periodontal wound dressing

OroScience plc (Palo Alto, CA), an oral care life science company, announced today that it has entered into an agreement with ACE Surgical Supply, Inc. (Brockton, MA) to market and distribute Periogenix periodontal wound dressing to clinicians in the United States and Canadian dental markets.

1 Jun 2010

Problems patients experience due to dental or skin conditions often misunderstood by care providers

Problems patients experience due to dental or skin conditions are often differently perceived by care providers. This is shown in a dissertation by Francesca Sampogna, a researcher in epidemiology at Istituto Dermopatico dell'Immacolata in Rome.

31 May 2010

NewYork-Presbyterian Hospital/Columbia University Medical Center announce presentations at American Urological Association meeting

Physician-scientists from NewYork-Presbyterian Hospital/Columbia University Medical Center will present their latest research findings at the American Urological Association Annual Meeting in San Francisco, May 29 to June 3.

31 May 2010

Athletic mouthguards reduce incidence and severity of dental injury

If you participate in organized sports or recreational activities, there's always the risk of injury to the mouth, says the American Dental Association (ADA).

31 May 2010

AAID's advice on teeth suddenly knocked out

Chicago Blackhawks star Duncan Keith's dental misfortune on the ice is an occupational hazard for hockey players, but teeth also can be lost in accidents, sports mishaps and falls that can happen to anyone. So what should you do when one or more of your teeth are suddenly knocked out?

29 May 2010

Some states calling for ultrasounds to limit abortion

News outlets report on state initiatives to limit abortions by requiring an ultrasound before the procedure. "Over the last decade, ultrasound has quietly become a new front in the grinding state-by-state battle over abortion," The New York Times reports.

29 May 2010

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced initiation of a Phase 2 proof-of-concept clinical trial to evaluate the preliminary efficacy and safety of its oncology drug candidate bafetinib in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL).

29 May 2010

VIVUS to present phase 3 data on avanafil for treatment of ED at AUA 2010

VIVUS, Inc. today announced that phase 3 data on avanafil, a next generation oral phosphodiesterase type 5 inhibitor therapy being investigated for the treatment of erectile dysfunction, will be presented next Tuesday at the American Urological Association 2010 Annual Meeting in San Francisco, California.

28 May 2010

BG Medicine announces data presentations on galectin-3 at Heart Failure Congress 2010

BG Medicine, Inc., a U.S. based, privately-held biomarker discovery and in vitro diagnostics company, announced today that there will be several data presentations regarding galectin-3 at the Heart Failure Congress 2010, the annual scientific meeting of the Heart Failure Association of the European Society of Cardiology, to be held in Berlin, Germany, on May 29th through June 1st. BG Medicine has developed and applied for FDA clearance of an in vitro diagnostic test to measure galectin-3 levels in plasma or serum.

28 May 2010

Philips partners with SickKids to improve oral health among Canadian children

In an effort to improve oral health among Canadian children, Philips, a global leader in health and well-being, today announced a partnership with The Hospital for Sick Children that will see Philips provide its Sonicare Power Toothbrushes to patients in the Hospital's dental clinic.

28 May 2010

Oral News and Research

New oral blood-thinning drugs may have dangerous interactions when taken with prescription drugs : Study

Perrigo acquires rights to Novel Laboratories' pending ANDA for HalfLytely and Bisacodyl Tablets Bowel Prep Kit

Chronix Biomedical to launch new disease detection, monitoring service for cancer researchers at 2010 ASCO

Targeted monoclonal antibodies show promise for pancreatic and metastatic breast cancer

Santarus commences enrollment in rifamycin SV MMX Phase III clinical program for travelers' diarrhea

Onyx Pharmaceuticals commences Phase 1 study of ONX 0912 oral proteasome inhibitor for cancer

Tetraphase Pharmaceuticals raises $45M in Series C financing

CoaguSense unveils first portable point-of-care PT/INR Monitoring System for patients on oral anticoagulants

Protox announces presentations on PRX302 for BPH at 2010 AUA Annual Meeting

Centocor Ortho Biotech acquires RespiVert

OroScience signs agreement with ACE Surgical Supply to market Periogenix periodontal wound dressing

Problems patients experience due to dental or skin conditions often misunderstood by care providers

NewYork-Presbyterian Hospital/Columbia University Medical Center announce presentations at American Urological Association meeting

Athletic mouthguards reduce incidence and severity of dental injury

AAID's advice on teeth suddenly knocked out

Some states calling for ultrasounds to limit abortion

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

VIVUS to present phase 3 data on avanafil for treatment of ED at AUA 2010

BG Medicine announces data presentations on galectin-3 at Heart Failure Congress 2010

Philips partners with SickKids to improve oral health among Canadian children

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News